OncLive TV

Dr Al Malki on Reducing Relapse Risk in Patients with MDS Undergoing Haplo-HSCT

February 7th 2025

Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.

Dr Krop on Zanidatamab Plus Evorpacept in HER2+ Metastatic Breast Cancer

February 7th 2025

Ian Krop, MD, PhD, discusses zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Dr Fenske on the Rationale of Assessing Rituximab With or Without ASCT in MRD-Negative MCL

February 6th 2025

Timothy S. Fenske, MD, MS, details the rationale of a phase 3 trial assessing rituximab with or without ASCT in mantle cell lymphoma.

Dr Garrido-Laguna on the Safety and Efficacy of Daraxonrasib in KRAS-Mutated PDAC

February 6th 2025

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses updated safety and efficacy data with daraxonrasib in KRAS-mutated pancreatic ductal adenocarcinoma.

Dr Fakih on Responses With Botensilimab Plus Balstilimab in MSS CRC

February 6th 2025

Marwan G. Fakih, MD, discusses response rates with botensilimab plus balstilimab in patients with microsatellite-stable colorectal cancer.

Dr Alderuccio on Loncastuximab Tesirine With Rituximab in R/R Follicular Lymphoma

February 6th 2025

Juan Pablo Alderuccio, MD, discusses the combination of loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma.

Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC

February 6th 2025

Tina Cascone, MD, PhD, discusses the efficacy and safety of neoadjuvant durvalumab plus novel agents or chemotherapy in resectable NSCLC.

Dr Werutsky on Assessing the Prognostic Value of HER2-Low in Early Breast Cancer

February 5th 2025

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis assessing the prognostic value of HER2-low in early breast cancer management.

Dr Sekeres on the Association Between Smoking and Disease Progression in MDS

February 5th 2025

Mikkael A. Sekeres, MD, discusses the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes.

Dr Muffly on the Role of Obe-Cel in R/R B-Cell Precursor ALL

February 5th 2025

Dr Phull on Real-World vs Trial Data for CAR T-Cell Therapy in R/R Multiple Myeloma

February 4th 2025

Pooja Phull, MD, highlights differences between real-world vs clinical trial data for cilta-cel vs ide-cel in relapsed/refractory multiple myeloma.

Dr Winer on Considerations for Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

February 4th 2025

Eric Winer, MD, discusses considerations for inavolisib plus palbociclib with fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

February 4th 2025

Jennifer Amengual, MD, discusses the efficacy of tazemetostat plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

February 4th 2025

Tom van Meerten, MD, PhD, discusses the role of brexucabtagene autoleucel in high-risk MCL.

Dr Bishop on the Potential Significance of Anito-Cel for the Multiple Myeloma Treatment Paradigm

February 3rd 2025

Michael R. Bishop, MD, discusses the potential significance of anitocabtagene autoleucel for the relapsed/refractory multiple myeloma treatment paradigm.

Dr Landgren on Recent Treatment Paradigm Changes in Multiple Myeloma

February 3rd 2025

C. Ola Landgren, MD, PhD, discusses the rapidly changing treatment paradigm within multiple myeloma.

Dr Bardia on the FDA Approval of Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer

February 3rd 2025

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of Dato-DXd for pretreated, hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

February 2nd 2025

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

February 2nd 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC

February 2nd 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.